search
Back to results

Computed Tomography Enterography (CTE) Versus Capsule Endoscopy for Overt, Obscure Gastrointestinal (GI) Bleeding

Primary Purpose

Recurrent Gastrointestinal Bleeding

Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Capsule Endoscopy
CT Enterography
Sponsored by
Brigham and Women's Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Recurrent Gastrointestinal Bleeding focused on measuring overt, obscure, gastrointestinal, bleeding, hemorrhage

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients presenting with signs and symptoms of "overt, obscure GI bleeding" including hematemesis, melena, and hematochezia within the past 14 days with negative endoscopic evaluation (including upper endoscopy for hematemesis, and both upper and lower endoscopy for hematochezia) despite clinical evidence of GI bleeding.

Exclusion Criteria:

  • Known renal insufficiency (or blood Creat >1.5 or estimated glomerular filtration rate [eGFR]<60)
  • Allergy to iodinated intravenous (IV) contrast media
  • Swallowing difficulties
  • Known small bowel strictures
  • Suspected bowel obstruction
  • Under the age of 18
  • Unable to give consent
  • Currently pregnant

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Overt Obscure Gastrointestinal Bleeders

    Arm Description

    The only cohort in this study are those patients identified as having overt, obscure gastrointestinal bleeding who will then undergo CE or CTE.

    Outcomes

    Primary Outcome Measures

    Detection of an actively bleeding lesion or lesion believed to be causing bleeding symptoms.
    Patients enrolled in the study will undergo either capsule endoscopy or CT enterography first, and this decision will generally be based on which test the clinical providers have already scheduled or availability of testing as is done with routine clinical care. The results of each the test will be read by an experienced gastroenterologist or radiologist respectively. These reviewers will be blinded to the results of any other diagnostic studies. The patient will then undergo the second test.

    Secondary Outcome Measures

    Contribution of diagnostic test to clinical management
    We will assess whether either CT or CTE changes managemet based on findings
    Overall cost of evaluation
    We will assess the cost of each test and cost based on findings
    Adverse events
    We will measure any and all adverse outcomes based on CT or CTE for the month following whichever study is performed last.

    Full Information

    First Posted
    April 29, 2010
    Last Updated
    August 7, 2013
    Sponsor
    Brigham and Women's Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01114295
    Brief Title
    Computed Tomography Enterography (CTE) Versus Capsule Endoscopy for Overt, Obscure Gastrointestinal (GI) Bleeding
    Official Title
    Comparative Effectiveness of Wireless Capsule Endoscopy and Dual Energy, Phase CT Enterography in the Evaluation of Overt Obscure GI Bleeding
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2013
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    The study was stopped before the first patient was enetered due to logistical issues and lack of funding.
    Study Start Date
    March 2010 (undefined)
    Primary Completion Date
    June 2011 (Actual)
    Study Completion Date
    January 2012 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Brigham and Women's Hospital

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Up to 5% of patients with recurrent gastrointestinal (GI) bleeding remain undiagnosed by upper endoscopy and colonoscopy, the presumed source of bleeding in these patients being the small intestine. These patients fall under the category of "obscure gastrointestinal bleeding," and frequently require an extensive diagnostic work-up. Obscure gastrointestinal bleeding (OGIB) refers to bleeding undiagnosed by upper endoscopy and colonoscopy. In 40-70% of cases of OGIB, a bleeding lesion is localizable to the small bowel. In OGIB, capsule endoscopy (CE) has a diagnostic yield of 40-80%, and has demonstrated diagnostic superiority to push enteroscopy, barium studies, angiography, CT angiography, and routine abdominal CT scan. When CE is non-diagnostic, however, the subsequent diagnostic algorithm is not well-defined. There is currently no established role for cross-sectional imaging for this indication. CT enterography (CTE) combines the spatial and temporal resolution of CT with an orally administered neutral enteric contrast material that permits detailed visualization of the small bowel. Unlike other imaging modalities such as nuclear medicine techniques and catheter angiography, CT is less labor-intensive, more readily available, and provides precise anatomic localization. A novel OGIB-protocol available at Brigham and Women's Hospital for CTE utilizes a dual-phase, dual energy technique that obtains images at two time points to better identify active bleeding in the mesentery. We, the investigators, plan to prospectively study an algorithm that employs CTE and compare to capsule endoscopy to investigate the effectiveness of both modalities and to evaluate the potential role of CTE in OGIB. The goal of our study is to determine observationally the contribution of both CE and the new protocol for CTE to the evaluation and management of overt obscure GI bleeding and accordingly revise the clinical algorithm. We hypothesize that CTE will be as or more effective than CE at identifying culprit lesions in overt, obscure gastrointestinal bleeding.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Recurrent Gastrointestinal Bleeding
    Keywords
    overt, obscure, gastrointestinal, bleeding, hemorrhage

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Overt Obscure Gastrointestinal Bleeders
    Arm Type
    Experimental
    Arm Description
    The only cohort in this study are those patients identified as having overt, obscure gastrointestinal bleeding who will then undergo CE or CTE.
    Intervention Type
    Device
    Intervention Name(s)
    Capsule Endoscopy
    Intervention Description
    Prior to the test, patients will be on a clear liquid diet for 24 hours and will have undergone an overnight fast. If a clear liquid diet is not possible, some patients may undergo a bowel preparation the day before the procedure. On the morning of the test, patients will swallow a video capsule with water. Clear liquids will be permitted after 2 hours, and a light meal permitted 4 hours after swallowing the capsule, if appropriate. No medications will be allowed 2 hours before the procedure and drugs that can delay gastric emptying will be avoided until the study is complete. At 8 hours after ingestion, the sensor array and recorder/battery belt pack will be disconnected and the data will be downloaded onto a computer equipped with software for image viewing. Images are sent through 8 skin electrodes to the recorder, stored and viewed on a RAPID workstation. At the end of the recording, the video is transferred to a computer for analysis.
    Intervention Type
    Radiation
    Intervention Name(s)
    CT Enterography
    Intervention Description
    CT enterography at the Brigham and Women's hospital is performed by using intravenous iodinated contrast material (Ultravist 300) and a neutral oral-enteric contrast material containing methylcellulose (Volumen). During scanning, 150 mL of nonionic intravenous contrast medium will be administered at a rate of 3mL/sec and the imaging conducted 40 and 70 seconds after the administration of the intravenous contrast medium. All imaging will be performed on a Dual-Energy multi-detector row CT scanner, Somatom Definition (Siemens Healthcare, Forcheim, Germany). Two independent X-ray tube/detector system will be used for image acquisition. One tube operates at 140 kV and the other at 80 kV . Slice collimation will be 0.6 mm and images reconstructed at 3 mm thickness with 3 mm reconstruction intervals. Coronal and sagittal images will be reconstructed at 3 mm thickness with 3 mm increments. Images will be reviewed by a radiologist experienced in the interpretation of CT enterography.
    Primary Outcome Measure Information:
    Title
    Detection of an actively bleeding lesion or lesion believed to be causing bleeding symptoms.
    Description
    Patients enrolled in the study will undergo either capsule endoscopy or CT enterography first, and this decision will generally be based on which test the clinical providers have already scheduled or availability of testing as is done with routine clinical care. The results of each the test will be read by an experienced gastroenterologist or radiologist respectively. These reviewers will be blinded to the results of any other diagnostic studies. The patient will then undergo the second test.
    Time Frame
    2-3 days
    Secondary Outcome Measure Information:
    Title
    Contribution of diagnostic test to clinical management
    Description
    We will assess whether either CT or CTE changes managemet based on findings
    Time Frame
    30 days
    Title
    Overall cost of evaluation
    Description
    We will assess the cost of each test and cost based on findings
    Time Frame
    30 days
    Title
    Adverse events
    Description
    We will measure any and all adverse outcomes based on CT or CTE for the month following whichever study is performed last.
    Time Frame
    30 days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patients presenting with signs and symptoms of "overt, obscure GI bleeding" including hematemesis, melena, and hematochezia within the past 14 days with negative endoscopic evaluation (including upper endoscopy for hematemesis, and both upper and lower endoscopy for hematochezia) despite clinical evidence of GI bleeding. Exclusion Criteria: Known renal insufficiency (or blood Creat >1.5 or estimated glomerular filtration rate [eGFR]<60) Allergy to iodinated intravenous (IV) contrast media Swallowing difficulties Known small bowel strictures Suspected bowel obstruction Under the age of 18 Unable to give consent Currently pregnant
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    John Saltzman, MD
    Organizational Affiliation
    Brigham and Women's Hospital
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Computed Tomography Enterography (CTE) Versus Capsule Endoscopy for Overt, Obscure Gastrointestinal (GI) Bleeding

    We'll reach out to this number within 24 hrs